Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Subcutaneous Lecanemab Vial vs Auto-Injector
NCT05533801Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Sep 2022
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lecanemab in Alzheimer's disease (AD) (2 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration at 1176 hours, Area Under the Serum Concentration-time Curve From Time Zero to Time Extrapolated to Infinity at 1176 hours and 3 more. Started Sep 2022; status: completed.
02
Drugs
lecanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05533801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05533801.